ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / ALZN / forecast
ACXP (33) BGMS (38) SKYE (34) APRE (40) ⌘ Pro Terminal →

Alzamend Neuro Inc. (ALZN) 12-Month Stock Forecast & Price Target Cone

$1.21 -0.82% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.21

Alzamend Neuro Inc. (ALZN) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →
ROARABLE E • RED ALERT Cap $5.8M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ALZN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ALZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Alzamend Neuro Inc. (NASDAQ: ALZN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.21 (-0.82% 1D, market cap $5.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ALZN ranks #656 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ALZN compare to ACXP and BGMS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALZN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACXP (Acurx Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M) and BGMS (Bio Green Med Solution Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $6.0M). Among the 5-stock peer group, ALZN leads on earnings multiple (N/A) while ALZN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ALZN?
▼

Per ALZN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001677077), Alzamend Neuro Inc. generated $0 in revenue, -$8.8M in net income, and -$8.1M in free cash flow against $4.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.21 (-0.34%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D
Cash (8)Whales (3)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-10.7% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE ALZN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALZN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY ALZN SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
42
Grade D$1.35-3.7% Next Q
Q2 (-2Q)
39
Grade E$1.30-13.1% Next Q
Q3 (-1Q)
37
Grade E$1.13+7.1% Next Q
Current
34
Grade E$1.21-8.7% Hist 90D α
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ALZN Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ALZN currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.52) and Max Pain ($1.27) forces dealer call-delta covering toward $2.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALZN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ALZN Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your ALZN Position Size: $10,000

Shares at $1.21: 8264.5 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $0.84
$6,942
$-3,058 (-30.6%)
12M Consensus BaseTarget $1.08
$8,926
$-1,074 (-10.7%)
12M Bull Case BreakoutTarget $2.74
$22,645
+$12,645 (+126.4%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$174%A
Goldman SachsSector Coverage LeadUNDERPERFORM$369%B
JP MorganUS Large-Cap ResearchSELL$158%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ALZN)

  • ✓Walkthrough of ALZN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ALZN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +9.01%📐 HORIZONTAL RANGE
2026-11-03O $1.22H $1.22L $1.21C $1.21VOL 25.0K
RES: $2.18SUP: $1.05SMA50: $1.52SMA200: $1.46
$2.18$1.86$1.54$1.22$0.90RES $2.18SUP $1.05$1.212026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALZN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALZN Butterfly Map → + Track ALZN →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ALZN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALZN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ALZN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALZN)

Health Care Rank #656 of 1016 ⚔️ ACXP vs ALZN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALZN vs. ACXP, BGMS, SKYE, APRE)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Alzamend Neuro Inc. (ALZN) ranks #656 by composite RQD confidence (34/100, grade E) and #928 by equity capitalization ($5.8M). Within this direct 5-issuer industry benchmark cohort, ALZN leads on earnings valuation at N/A trailing P/E, while ALZN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APRE currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with ALZN at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ALZN ACTIVE
Alzamend Neuro Inc.
E 34/100 — — -35.0% -0.82% $5.8M Benchmark Subject
ACXP
Acurx Pharmaceuticals Inc.
E 33/100 — — -35.0% -2.80% $5.8M /acxp-vs-alzn →
BGMS
Bio Green Med Solution Inc.
D- 38/100 — — -35.0% +8.43% $6.0M /bgms-vs-alzn →
SKYE
Skye Bioscience Inc.
E 34/100 — — -35.0% -2.29% $5.7M /skye-vs-alzn →
APRE
Aprea Therapeutics Inc.
D- 40/100 — — -35.0% -1.82% $6.1M /apre-vs-alzn →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-04-30 • CIK 0001677077

In its most recent audited fiscal period (FY2025, filed 2026-04-30), Alzamend Neuro Inc. (ALZN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$8.8M, operating cash flow of -$8.1M, and free cash flow of -$8.1M (-22.8% YoY). On the balance sheet, ALZN closed FY2025 with $4.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-04-30 $0 -$8.8M -$8.1M -$8.1M $4.0M —
FY2024 (FY) 2025-04-30 $0 -$4.5M -$6.6M -$6.6M $4.2M —
FY2023 (FY) 2024-04-30 $0 -$9.9M -$8.3M -$8.3M — —

3. ALZN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Alzamend Neuro Inc. (NASDAQ: ALZN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.21 (-0.82% 1D, market cap $5.8M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, ALZN ranks #656 in composite RQD confidence.

How does ALZN compare to ACXP and BGMS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALZN carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACXP (Acurx Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M) and BGMS (Bio Green Med Solution Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $6.0M). Among the 5-stock peer group, ALZN leads on earnings multiple (N/A) while ALZN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ALZN?

Per ALZN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0001677077), Alzamend Neuro Inc. generated $0 in revenue, -$8.8M in net income, and -$8.1M in free cash flow against $4.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ALZN trading relative to its 50-day, 200-day, and 52-week technical levels?

ALZN last traded at $1.21 (-0.82% on volume of 25,032 shares), positioning the stock -20.39% below its 50-day simple moving average ($1.52) and -17.12% below its 200-day simple moving average ($1.46). Across its 52-week range of $0.84 to $2.61, ALZN sits at the 20.9% percentile with a 14-day RSI of 38.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.06 to $1.36).

ALZN Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ALZN's 12-month stock price target?

Alzamend Neuro Inc. (ALZN) carries a 12-month consensus base price target of $1.08 (-10.7% from $1.21), with a bull-case target of $2.74 and a bear-case floor of $0.84.

Is ALZN stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates ALZN E (Strong Sell — SELL) with an RQD Confidence score of 34/100.

Direct Sub-Reports: ALZN RQD Cockpit ALZN 12M Forecast ALZN Earnings & Move ALZN Dividends & DRIP ALZN Insiders & 13F ALZN Whale Options ALZN Profit Sankey ALZN News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ STAGE-C NUMBER FIREWALL VERIFIED

ALZN — Alzamend Neuro Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:52:55Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ALZN scores 35 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

  • Fundamental Cash Engine: 8 / 20 (ROIC -35%; FCF yield 0%). Negative return on invested capital and zero free-cash-flow yield indicate the business is consuming capital rather than generating it.
  • Whale / 13F Flow: 3 / 20 (institutional accumulation and options positioning). This is the weakest pillar, suggesting little supportive institutional demand in the source data.
  • Insider Conviction: 5 / 20 (SEC Form 4 and Congressional PTR cluster flow). Insider and congressional signals are weak.
  • Macro Regime Fit: 9 / 20 (Beta 1.0; sector sensitivity). A beta of 1.0 means the stock moves in line with the broader market, with no defensive cushion indicated.
  • Forensic Balance Sheet: 10 / 20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). The Piotroski F-Score of 1 out of 9 is a notably weak reading on financial health.

For a prospective investor, the rating implies that upside depends on a turnaround in cash generation that the reported financials do not yet show, while the balance sheet and flow pillars offer limited support. Valuation cannot be assessed on earnings because P/E and EPS are not available in source data; the market capitalization of $5.9M against reported net losses of $-8.8M in FY 2025 frames the risk profile. This is an analytical summary, not personalized financial advice.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$0.0M$-8.8M$-8.8MN/A$-8.1M$2.7MN/A
FY 2024$0.0M$-4.5M$-4.5MN/A$-6.6M$3.4MN/A
FY 2023$0.0M$-9.9M$-9.9MN/A$-8.3MN/AN/A

Per the SEC financials, the company reported no revenue and operating losses in each period shown, with gross, operating, and net margins all at 0% in the market data. ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1 out of 9, with Debt/Equity at 0.5. Cash declined from $3.4M to $2.7M between FY 2024 and FY 2025 while free cash flow remained negative.

Open Questions

  • What are the company's products, clinical programs, or licensing arrangements, and what revenue, if any, is expected?
  • What is the cash runway given $2.7M of cash against FY 2025 free cash flow of $-8.1M?
  • What is the debt position, since reported debt is N/A while Debt/Equity is 0.5?
  • What drove the reported upgrade to Buy, and does it reflect company-specific fundamentals?
  • Why are EPS and valuation multiples unavailable, and how should earnings-based valuation be approached?

ALZN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Alzamend Neuro Inc. (ALZN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ALZN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ALZN Bull vs. Bear Conversation Board — What's Your Call at $1.21?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALZN 🐻 67% BEARISH CONVICTION
1. Pick Your Side on ALZN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.07 (-12.3%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is ALZN (D- • RQD 35/100) a Buy at $1.22?

Welcome to the ALZN (Alzamend Neuro Inc.) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

MU MultipleCompression Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.99 (-18.9%)
Spot @ $1.22

Pump the brakes on ALZN — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ALZN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Alzamend Neuro Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.49 (+22.1%)
Spot @ $1.22

ALZN cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ALZN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.22 (52-wk range $0.84 - $2.68), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%